T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
(DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001.NCT04622319 )
Introduction
A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)
Trial overview was presented at the GBG annual meeting 2021.See the video online or download the slides here.
News
Trials is open for recruting.
More downloads
Contact
Project management
Dr. Ioannis Gkantiragas
Viktoria Tierbach
destiny-b05@gbg.de
+49 6102 7480-440
